Back from the Brink: EGFR Inhibition in Gastroesophageal Cancer

Back from the Brink: EGFR Inhibition in Gastroesophageal Cancer

Gastroesophageal adenocarcinomas (GEA) remain difficult to treat with limited targeted therapeutics. Negative results from randomized trials of EGFR inhibitors (EGFRi) in patients with molecularly unselected GEA have hampered the development of EGFRi in the gastroesophageal cancer space. A recent st...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical cancer research 2021-06, Vol.27 (11), p.2964-2966
Hauptverfasser: Openshaw, Mark R, Pinato, David J, Valeri, Nicola
Format: Artikel
Sprache:eng
Schlagworte:
Adenocarcinoma
ErbB Receptors - genetics
Esophageal Neoplasms - drug therapy
Humans
Stomach Neoplasms - drug therapy
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2966
container_issue 11
container_start_page 2964
container_title Clinical cancer research
container_volume 27
creator Openshaw, Mark R
Pinato, David J
Valeri, Nicola
description Gastroesophageal adenocarcinomas (GEA) remain difficult to treat with limited targeted therapeutics. Negative results from randomized trials of EGFR inhibitors (EGFRi) in patients with molecularly unselected GEA have hampered the development of EGFRi in the gastroesophageal cancer space. A recent study reopens the game. .
doi_str_mv 10.1158/1078-0432.CCR-21-0533
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7617050</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2506277679</sourcerecordid><originalsourceid>FETCH-LOGICAL-c359t-a6c604d10d076c15e69e3d7901422c8de23d71ce2ef3e5351da0ae3f6ce2e9303</originalsourceid><addsrcrecordid>eNpVkF1PwjAUhhujEUR_gmaX3gz7sbbMC40sgCQkJkSvm9KdQWWs2A4T_71b-Ihena_3vOfkQeiW4D4hfPBAsBzEOGG0n2XzmJIYc8bOUJdwLmNGBT9v8qOmg65C-MSYJAQnl6jDmJRkwGkXPQ-1WUeFd5uoXkE09LZaP0ajyXgeTauVXdjauiqyVTTRofYOgtuu9BJ0GWW6MuCv0UWhywA3h9hDH-PRe_Yaz94m0-xlFhvG0zrWwgic5ATnWApDOIgUWC7T5iNKzSAH2lTEAIWCAWec5BprYIVoWynDrIee9r7b3WIDuYGq9rpUW2832v8op636P6nsSi3dt5KCSMxbg_uDgXdfOwi12thgoCx1BW4XFOVYUCmFTBsp30uNdyF4KE5nCFYtfNWCVS1Y1cBXlKgWfrN39_fH09aRNvsFiBt_yQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2506277679</pqid></control><display><type>article</type><title>Back from the Brink: EGFR Inhibition in Gastroesophageal Cancer</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Openshaw, Mark R ; Pinato, David J ; Valeri, Nicola</creator><creatorcontrib>Openshaw, Mark R ; Pinato, David J ; Valeri, Nicola</creatorcontrib><description>Gastroesophageal adenocarcinomas (GEA) remain difficult to treat with limited targeted therapeutics. Negative results from randomized trials of EGFR inhibitors (EGFRi) in patients with molecularly unselected GEA have hampered the development of EGFRi in the gastroesophageal cancer space. A recent study reopens the game. .</description><identifier>ISSN: 1078-0432</identifier><identifier>ISSN: 1557-3265</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.CCR-21-0533</identifier><identifier>PMID: 33771852</identifier><language>eng</language><publisher>United States</publisher><subject>Adenocarcinoma ; ErbB Receptors - genetics ; Esophageal Neoplasms - drug therapy ; Humans ; Stomach Neoplasms - drug therapy</subject><ispartof>Clinical cancer research, 2021-06, Vol.27 (11), p.2964-2966</ispartof><rights>2021 American Association for Cancer Research.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c359t-a6c604d10d076c15e69e3d7901422c8de23d71ce2ef3e5351da0ae3f6ce2e9303</cites><orcidid>0000-0001-6973-3067</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,3343,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33771852$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Openshaw, Mark R</creatorcontrib><creatorcontrib>Pinato, David J</creatorcontrib><creatorcontrib>Valeri, Nicola</creatorcontrib><title>Back from the Brink: EGFR Inhibition in Gastroesophageal Cancer</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>Gastroesophageal adenocarcinomas (GEA) remain difficult to treat with limited targeted therapeutics. Negative results from randomized trials of EGFR inhibitors (EGFRi) in patients with molecularly unselected GEA have hampered the development of EGFRi in the gastroesophageal cancer space. A recent study reopens the game. .</description><subject>Adenocarcinoma</subject><subject>ErbB Receptors - genetics</subject><subject>Esophageal Neoplasms - drug therapy</subject><subject>Humans</subject><subject>Stomach Neoplasms - drug therapy</subject><issn>1078-0432</issn><issn>1557-3265</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkF1PwjAUhhujEUR_gmaX3gz7sbbMC40sgCQkJkSvm9KdQWWs2A4T_71b-Ihena_3vOfkQeiW4D4hfPBAsBzEOGG0n2XzmJIYc8bOUJdwLmNGBT9v8qOmg65C-MSYJAQnl6jDmJRkwGkXPQ-1WUeFd5uoXkE09LZaP0ajyXgeTauVXdjauiqyVTTRofYOgtuu9BJ0GWW6MuCv0UWhywA3h9hDH-PRe_Yaz94m0-xlFhvG0zrWwgic5ATnWApDOIgUWC7T5iNKzSAH2lTEAIWCAWec5BprYIVoWynDrIee9r7b3WIDuYGq9rpUW2832v8op636P6nsSi3dt5KCSMxbg_uDgXdfOwi12thgoCx1BW4XFOVYUCmFTBsp30uNdyF4KE5nCFYtfNWCVS1Y1cBXlKgWfrN39_fH09aRNvsFiBt_yQ</recordid><startdate>20210601</startdate><enddate>20210601</enddate><creator>Openshaw, Mark R</creator><creator>Pinato, David J</creator><creator>Valeri, Nicola</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6973-3067</orcidid></search><sort><creationdate>20210601</creationdate><title>Back from the Brink: EGFR Inhibition in Gastroesophageal Cancer</title><author>Openshaw, Mark R ; Pinato, David J ; Valeri, Nicola</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c359t-a6c604d10d076c15e69e3d7901422c8de23d71ce2ef3e5351da0ae3f6ce2e9303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adenocarcinoma</topic><topic>ErbB Receptors - genetics</topic><topic>Esophageal Neoplasms - drug therapy</topic><topic>Humans</topic><topic>Stomach Neoplasms - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Openshaw, Mark R</creatorcontrib><creatorcontrib>Pinato, David J</creatorcontrib><creatorcontrib>Valeri, Nicola</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Openshaw, Mark R</au><au>Pinato, David J</au><au>Valeri, Nicola</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Back from the Brink: EGFR Inhibition in Gastroesophageal Cancer</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2021-06-01</date><risdate>2021</risdate><volume>27</volume><issue>11</issue><spage>2964</spage><epage>2966</epage><pages>2964-2966</pages><issn>1078-0432</issn><issn>1557-3265</issn><eissn>1557-3265</eissn><abstract>Gastroesophageal adenocarcinomas (GEA) remain difficult to treat with limited targeted therapeutics. Negative results from randomized trials of EGFR inhibitors (EGFRi) in patients with molecularly unselected GEA have hampered the development of EGFRi in the gastroesophageal cancer space. A recent study reopens the game. .</abstract><cop>United States</cop><pmid>33771852</pmid><doi>10.1158/1078-0432.CCR-21-0533</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0001-6973-3067</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1078-0432
ispartof Clinical cancer research, 2021-06, Vol.27 (11), p.2964-2966
issn 1078-0432
1557-3265
1557-3265
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7617050
source MEDLINE; American Association for Cancer Research; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Adenocarcinoma
ErbB Receptors - genetics
Esophageal Neoplasms - drug therapy
Humans
Stomach Neoplasms - drug therapy
title Back from the Brink: EGFR Inhibition in Gastroesophageal Cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T13%3A39%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Back%20from%20the%20Brink:%20EGFR%20Inhibition%20in%20Gastroesophageal%20Cancer&rft.jtitle=Clinical%20cancer%20research&rft.au=Openshaw,%20Mark%20R&rft.date=2021-06-01&rft.volume=27&rft.issue=11&rft.spage=2964&rft.epage=2966&rft.pages=2964-2966&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/10.1158/1078-0432.CCR-21-0533&rft_dat=%3Cproquest_pubme%3E2506277679%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2506277679&rft_id=info:pmid/33771852&rfr_iscdi=true